Medical Reportingidentity—cleaved egg, ovasome, truck,pre-embryo, pluripotent stem cells,etc.—to distinguish it from other humanembryos deemed worthy of life.Needless to say, no one calls the unembryos“subhumans.”Neither this new terminology northis secular creationism has been challengedby any of the major newspapers—notin editorials nor in reporting.Translated into the dot-comscenario, such practices are akin toreporters accepting assurances fromcorporate executives that their financiallosses are really investments andprojected revenue is bankable cash.Come to think of it, that’s what manydot-coms did to hide their red ink,without it being described that way byreporters for months or years, until theEnron collapse precipitated the returnof common sense.De<strong>live</strong>ring What ReportingPromisesCures that seemed so promising in thefirst wave of stem cell stories mightnever arrive, simply because there istoo great a legal risk. The risk is thatone or more of the millions of stemcells transplanted from a cloned unhumanembryo into a patient will actuallytry to grow into a complete person.Each attempt will fail, of course, becausethe stem cell will have been extractedfrom its parent cloned embryo.But in the trying, such cells often nowgrow into “teratomas,” cancer-likegrowths of skin and bone, teeth andhair, and these would kill the patient.Optimistically, assume the cloningscientists can control the process 99out of 100 times. Those odds, whileacceptable to dying patients, will likelyruin commercial prospects for any cloning-basedtherapy, especially when oneadds the cost of custom cloning andconsiders marketplace competitionfrom drug-makers, surgeons and theadult stem cell therapies.Rival stem cell cures exist now, albeitin small numbers. Many cancerpatients are treated with their ownstem cells, and increasing numbers ofpatients with heart conditions, eyeproblems, brittle-bone disease, andmultiple sclerosis are also being treatedwith modest but significant successes.These treatments, so far, show no signof killing their patients.But the major media typically ignorethese advances and have evenrecently taken to labeling them as “celltherapy” or even just plain “stem cell”successes. This reporting tends to masktheir current therapeutic advantageover the much-touted use of stem cellsfrom cloned embryos. So far, no onehas been treated with embryos’ stemcells, although proponents argue thatthe first clinical trials could begin inthree to 10 years. That delay gives thetechnology of adults’ stem cell manyyears to run further ahead of the embryotechnology.Back in our comparative dot-comland, this misplaced focus is akin toreporters arguing that investors shouldembrace companies with high onlinemarket share or impressive stock valuations,rather than real products, actualprofits, and satisfied consumers.But that is precisely what many reportersand TV anchors did when theyfocused attention on companies whoselack of bankable assets was supposedlycountered by their coolness. Rememberpets.com? Who can possibly forgetclickmango.com, or Blue MountainArts, a dot-com company that was purchasedfor one billion dollars in cashand stock because it was expected tocorner the market on electronic greetingscards? The buyer, by the way, haslong since shut its doors, although theseller is living comfortably in Colorado.Speaking of value, one should askwho gains from the optimistic focus onembryos’ stem cells? The answer is afew companies and a variety of universitiesand scientists who hope the technologywill lead to higher stock priceson Wall Street, more federal grants,and greater prestige in the science community.Already, scientists working onadults’ stem cells say on the record—and with evidence to back them up—that the National Institutes of Health(NIH) favors the embryo stem cell technologythat was developed at the <strong>University</strong>of Wisconsin-Madison. (This, ofcourse, is no surprise to Tommy Thompson,the secretary of the Departmentof Health and Human Services,who previously served as governor ofWisconsin and who, in 2000, offered$150 million in state funds to boostlocal research on the technology.)The NIH’s focus on this technologyalso serves the interests of the embryoscientists—and their many fans amongscience reporters—who want to usecloned embryos to learn more aboutearly human development, both becauseof their desire to know and becauseof their desire to control thegenetics of early human development.One hopes that such control would beused to develop various cures for diseasesinvolving new types of drugs, forexample. But it might be used for anotherpurpose, such as earning plauditsneeded for academic prizes. Or itcould be used to win patents for thenascent genetic engineering industry,which hopes to profit from parents-tobewho are interested in shaping thedevelopment of their child while it isstill in the un-human petri-dish stage oflife.One should also ask who loses if thefocus remains on long-term researchinto human development. Arguably,the losers are the scientists who needgrants to further develop the technologyof adults’ stem cells and today’spatients who need short-term cures tosave them before they die. That’s thenot-implausible claim made from awheelchair by James Kelly, who wantssome of the money spent on usingstem cells to repair spinal cords, includinghis own. Disillusioned by theNIH’s spending, he’s looking overseasfor an adult stem cell cure. Even someadvocates in the “patients groups”—mostly funded and overseen by theprofessionals and managers who treatthe patients—have spoken out againstthe false promises of early cures fromembryo research.When translated back into the familiarterms of coverage of the dot-combust, the media’s focus on embryo workis akin to reporting that vaporware—software that does not exist—is betterthan partly tested software. It is littledifferent from reporting that a dotcom’sambitious hopes to dominate24 <strong>Nieman</strong> Reports / Summer <strong>2003</strong>
Medical Reportingonline retail make it a better investmentthan retail chains with expertise,warehouses, customers and revenue.Have journalists not learned fromthe dot-com bubble? Can we, as reporters,not restrain our wildest dreams infavor of accurately describing the limited,but still wonderful, progress thatwe observe?Our key error seems to be unwarranteddeference to professionals inthe universities and sciences. This fostersa widespread reluctance to treatscientists (whether they’re sources,subscribers or friends) as who theyreally are—university-based entrepreneursworking in a complex of professionaland commercial interests. Mostscientists, along with many other professionals,prefer to downplay wealthwhile they compete for and then advertisethe professional status that is oftenthe key to wealth and further professionalstatus.The media’s deference to the scientists’self-image is not universal, but itis routine. For example, both Rick Weissat The Washington Post and NicholasWade at The New York Times—whoreport many of these stories—explainedthat they usually did not includein their articles mention of thefinancial interests of the scientists becausethese interests are so commonplace.In my interview with Wade, whichI conducted while writing a freelancepiece for The Washington Monthly, healso told me that readers are not interestedin financial matters. And the approachthese influential reporters takeis similar to that taken by the vastmajority of journalists who write andedit these stories.But financial matters and professionalrivalries are not merely “fit toprint.” They’re central to the story ofbiotech, science and cloning. ■Neil Munro covers the politics ofscience and technology for the NationalJournal in Washington, D.C.Previously, he covered the dot-combubble for Washington Technologyand the U.S. Department of Defensefor Defense News.nmunro@njdc.comReporting the Cloning Story: From Hype toHealthy SkepticismJournalists can produce stronger stories by scrutinizing the motives,finances and personalities of researchers.By Aaron ZitnerThe scene was the National Academyof Sciences, the palace ofthe American scientific establishment.Marble columns. Walnut paneling.One of the neoclassical buildingsthat give Washington, D.C. its imperialfeel. Only on this day, the building washome more to circus than science.That’s how it felt to be in the throng ofreporters chasing three self-describedcloning researchers around the foyersand Great Hall, trying to press them ontheir alleged plans to clone humanbeings.It was August 2001, and the presswas beginning to grapple with the prospectof human cloning. The three“cloners” had been invited to speak ata conference on the subject, and ateach break we would pounce. Wechased Brigitte Boisselier into a dimlylit stairway, where she’d hoped to con-fer with her lawyer. We chased Italianfertility doctor, Severino Antinori, tothe men’s bathroom and then—in oneof the day’s few gestures of restraint—waited outside as he conducted hisbusiness. When he emerged, Antinoriwas greeted by a crowd of reportersand a half-dozen camera lights.Of course, this is just what Boisselierand the other cloning advocateswanted. They were there to gain attentionand ultimately, I believe, to makemoney on their cloning claims by attractinginvestors or clients. And weobliged them with stories that introducedtheir names to people aroundthe world—Antinori, his then-colleaguePanos Zavos, and Boisselier, an officialwith the once-obscure Raelian Movement,a religious group fixated on sexand UFO’s. We, in the media, madethem famous.Hyping the Cloning StoryIn itself, I saw nothing wrong with this.Personality is a key ingredient in thecloning story, which is also a rich combinationof science, sex, business, ethicsand very serious questions aboutlegal constraints on disease research—spiced with a generous dollop of creepiness.It’s an irresistible mix for anyreporter. Besides, it was the nationalacademy that gave the cloning advocatesthe podium that day; the mediafollowed the academy’s lead. (And,before that, Zavos, Boisselier and herreligious mentor, who goes by the nameRael, had been called to testify by noneother than the House of Representatives.)But as we chased this rich story, asjournalists we could—and should—have done much better for news con-<strong>Nieman</strong> Reports / Summer <strong>2003</strong> 25